Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MediWound (MDWD) Non-Current Deffered Revenue (2016 - 2022)

Historic Non-Current Deffered Revenue for MediWound (MDWD) over the last 7 years, with Q3 2022 value amounting to $31000.0.

  • MediWound's Non-Current Deffered Revenue fell 9119.32% to $31000.0 in Q3 2022 from the same period last year, while for Sep 2022 it was $31000.0, marking a year-over-year decrease of 9119.32%. This contributed to the annual value of $119000.0 for FY2021, which is 9035.66% down from last year.
  • Per MediWound's latest filing, its Non-Current Deffered Revenue stood at $31000.0 for Q3 2022, which was down 9119.32% from $61000.0 recorded in Q2 2022.
  • Over the past 5 years, MediWound's Non-Current Deffered Revenue peaked at $1.3 million during Q1 2018, and registered a low of $31000.0 during Q3 2022.
  • In the last 5 years, MediWound's Non-Current Deffered Revenue had a median value of $1.1 million in 2019 and averaged $835421.1.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first skyrocketed by 3557.79% in 2018, then crashed by 9119.32% in 2022.
  • Over the past 5 years, MediWound's Non-Current Deffered Revenue (Quarter) stood at $1.2 million in 2018, then fell by 1.99% to $1.1 million in 2019, then grew by 8.72% to $1.2 million in 2020, then tumbled by 90.36% to $119000.0 in 2021, then plummeted by 73.95% to $31000.0 in 2022.
  • Its Non-Current Deffered Revenue stands at $31000.0 for Q3 2022, versus $61000.0 for Q2 2022 and $91000.0 for Q1 2022.